tradingkey.logo

BRIEF-Cumberland Pharmaceuticals Announces Phase 2 Fight Dmd Trial Results For Duchenne Muscular Dystrophy Heart Disease

ReutersFeb 4, 2025 12:42 PM

- Cumberland Pharmaceuticals Inc CPIX.O:

  • CUMBERLAND PHARMACEUTICALS ANNOUNCES BREAKTHROUGH RESULTS FROM THE PHASE 2 FIGHT DMD TRIAL IN DUCHENNE MUSCULAR DYSTROPHY HEART DISEASE

  • CUMBERLAND PHARMACEUTICALS INC - IFETROBAN WELL-TOLERATED WITH NO SERIOUS DRUG-RELATED EVENTS

Source text: ID:nPn9B7wCBa

Further company coverage: CPIX.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI